Benzinga | Jul 7, 2021 07:46AM EDT

Jazz Pharmaceuticals Announces Health Canada Approval Of Vyxeos

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the Health Canada approval and availability of Vyxeos(r) (daunorubicin and cytarabine liposome for injection) for the treatment of adults with newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).1